128 related articles for article (PubMed ID: 29552770)
1. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
Qiu F; Zhao X
J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
[TBL] [Abstract][Full Text] [Related]
2. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
[TBL] [Abstract][Full Text] [Related]
3. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
5. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
6. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP
Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
[TBL] [Abstract][Full Text] [Related]
7. In vitro responses of ovarian cancers to platinums and taxanes.
Kornblith P; Wells A; Gabrin MJ; Piwowar J; Chattopadhyay A; George LD; Ochs RL; Burholt D
Anticancer Res; 2003; 23(1B):543-8. PubMed ID: 12680143
[TBL] [Abstract][Full Text] [Related]
8. [ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Zhang Y; Zhao Q; Jiang Y; Yuan Z; Yang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 38(12):1223-7. PubMed ID: 24384959
[TBL] [Abstract][Full Text] [Related]
9. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
10. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
Chou TC; Motzer RJ; Tong Y; Bosl GJ
J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
[TBL] [Abstract][Full Text] [Related]
11. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
[TBL] [Abstract][Full Text] [Related]
12. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Dorie MJ; Brown JM
Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
[TBL] [Abstract][Full Text] [Related]
13. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
14. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
Jonsson E; Fridborg H; Nygren P; Larsson R
Eur J Clin Pharmacol; 1998 Sep; 54(7):509-14. PubMed ID: 9832291
[TBL] [Abstract][Full Text] [Related]
16. Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach.
Ben-Arye E; Lavie O; Samuels N; Khamaisie H; Schiff E; Raz OG; Mahajna J
Med Oncol; 2017 Apr; 34(4):54. PubMed ID: 28238155
[TBL] [Abstract][Full Text] [Related]
17. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
18. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers.
Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE
Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477
[TBL] [Abstract][Full Text] [Related]
19. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Brickelmaier M; Carmillo A; Goelz S; Barsoum J; Qin XQ
J Interferon Cytokine Res; 2002 Aug; 22(8):873-80. PubMed ID: 12396726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
